Mizuho Securities Co. Ltd. Trims Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Mizuho Securities Co. Ltd. lessened its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 67.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 120 shares of the medical equipment provider’s stock after selling 250 shares during the quarter. Mizuho Securities Co. Ltd.’s holdings in Intuitive Surgical were worth $59,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Schrum Private Wealth Management LLC increased its position in Intuitive Surgical by 6.6% during the third quarter. Schrum Private Wealth Management LLC now owns 2,738 shares of the medical equipment provider’s stock valued at $1,345,000 after acquiring an additional 169 shares during the last quarter. ICICI Prudential Asset Management Co Ltd grew its holdings in Intuitive Surgical by 19.0% during the third quarter. ICICI Prudential Asset Management Co Ltd now owns 4,638 shares of the medical equipment provider’s stock valued at $2,279,000 after purchasing an additional 742 shares during the period. Kovack Advisors Inc. grew its holdings in Intuitive Surgical by 10.8% during the third quarter. Kovack Advisors Inc. now owns 1,388 shares of the medical equipment provider’s stock valued at $682,000 after purchasing an additional 135 shares during the period. Oppenheimer Asset Management Inc. grew its holdings in Intuitive Surgical by 2.0% during the third quarter. Oppenheimer Asset Management Inc. now owns 56,155 shares of the medical equipment provider’s stock valued at $27,587,000 after purchasing an additional 1,122 shares during the period. Finally, Pinnacle Financial Partners Inc grew its holdings in Intuitive Surgical by 4.5% during the third quarter. Pinnacle Financial Partners Inc now owns 22,492 shares of the medical equipment provider’s stock valued at $11,050,000 after purchasing an additional 972 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Activity

In related news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares in the company, valued at $1,461,006.84. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Amy L. Ladd sold 450 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the sale, the director now directly owns 821 shares of the company’s stock, valued at approximately $402,519.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 91,178 shares of company stock worth $45,897,071 over the last three months. Corporate insiders own 0.80% of the company’s stock.

Wall Street Analyst Weigh In

ISRG has been the subject of several recent research reports. Stifel Nicolaus boosted their price target on Intuitive Surgical from $475.00 to $525.00 and gave the company a “buy” rating in a report on Friday, October 18th. Wells Fargo & Company upped their price objective on Intuitive Surgical from $466.00 to $549.00 and gave the stock an “overweight” rating in a research note on Friday, October 18th. The Goldman Sachs Group set a $604.00 price target on Intuitive Surgical in a research note on Friday, October 18th. Evercore ISI reissued a “cautious” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. Finally, Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price objective for the company from $380.00 to $510.00 in a research report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Stock Performance

NASDAQ:ISRG traded down $0.27 during mid-day trading on Wednesday, reaching $536.80. The stock had a trading volume of 237,107 shares, compared to its average volume of 1,454,004. The firm has a market capitalization of $191.20 billion, a price-to-earnings ratio of 86.35, a PEG ratio of 5.27 and a beta of 1.39. Intuitive Surgical, Inc. has a twelve month low of $287.98 and a twelve month high of $542.59. The business has a 50 day simple moving average of $495.85 and a 200 day simple moving average of $455.08.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, topping the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The firm had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.01 billion. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.